HomeSHTDY • OTCMKTS
add
Sinopharm Group ADR
Previous close
$13.00
Day range
$13.26 - $13.36
Year range
$10.77 - $14.87
Market cap
65.28B HKD
Avg Volume
78.07K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (CNY) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 143.69B | 1.13% |
Operating expense | 5.00B | -10.42% |
Net income | 1.85B | 4.36% |
Net profit margin | 1.29 | 3.20% |
Earnings per share | — | — |
EBITDA | 5.97B | -2.51% |
Effective tax rate | 30.30% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 48.80B | -10.16% |
Total assets | 390.36B | -0.63% |
Total liabilities | 256.20B | -3.74% |
Total equity | 134.16B | — |
Shares outstanding | 3.12B | — |
Price to book | 0.48 | — |
Return on assets | 3.34% | — |
Return on capital | 6.42% | — |
Cash Flow
Net change in cash
| (CNY) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 1.85B | 4.36% |
Cash from operations | 53.22B | -10.21% |
Cash from investing | -1.21B | 67.09% |
Cash from financing | -30.23B | 18.95% |
Net change in cash | 21.77B | 19.12% |
Free cash flow | 24.05B | — |
About
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Founded
2003
Website
Employees
94,910
